In a filing, PTC Therapeutics Inc revealed its Officer Boulding Mark Elliott acquired Company’s shares for reported $3.61 million on Mar 10 ’25. In the deal valued at $53.09 per share,68,039 shares were bought.
Then, Jacobson Allan Steven sold 1,230 shares, generating $63,370 in total proceeds. Upon selling the shares at $51.52, the Director now owns 19,118 shares.
Before that, Jacobson Allan Steven bought 1,230 shares. PTC Therapeutics Inc shares valued at $63,365 were divested by the Director at a price of $51.52 per share.
Scotiabank initiated its PTC Therapeutics Inc [PTCT] rating to a Sector perform in a research note published on March 07, 2025; the price target was $55. A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who increased its forecast for the stock in mid December from “an Equal-weight” to “an Overweight”. RBC Capital Mkts also remained covering PTCT and has increased its forecast on December 03, 2024 with a “an Outperform” recommendation from previously “Sector perform” rating.
Price Performance Review of PTCT
On Monday, PTC Therapeutics Inc [NASDAQ:PTCT] saw its stock fall -0.19% to $52.49. Over the last five days, the stock has lost -0.72%. PTC Therapeutics Inc shares have risen nearly 16.28% since the year began. Nevertheless, the stocks have risen 69.98% over the past one year. While a 52-week high of $55.60 was reached on 03/03/25, a 52-week low of $24.00 was recorded on 01/14/25. SMA at 50 days reached $47.91, while 200 days put it at $40.15.
Levels Of Support And Resistance For PTCT Stock
The 24-hour chart illustrates a support level at 51.54, which if violated will result in even more drops to 50.59. On the upside, there is a resistance level at 53.63. A further resistance level may holdings at 54.77. The Relative Strength Index (RSI) on the 14-day chart is 58.41, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.97, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 27.55%. Stochastics %K at 73.66% indicates the stock is a holding.
The most recent change occurred on September 04, 2024 when Robert W. Baird began covering the stock and recommended ‘”an Outperform”‘ rating along with a $44 price target.
